Colgate-Palmolive is a consumer staples company, and its sell-side coverage is meaningful but centered near the current share price. Across roughly 18 to 21 current analyst targets, the average lands around $98, with a range that runs from approximately $80 to $110. Recent individual targets include J.P. Morgan at $104, UBS at $106, RBC Capital at $104, Morgan Stanley at $104, Citi at $110, Deutsche Bank at $101, Goldman Sachs and Evercore ISI at $100, and more cautious views from Barclays at $87 and TD Cowen at $90.
Because that overall mean represents only a single-digit-percentage premium to the share price, and because the average of just the above-price targets (about $102) is still only around 8% higher, these figures do not meet the threshold needed for a meaningful "reach" analysis. The $115 figure therefore reflects a publicly discussed, valuation-driven scenario — appearing in independent commentary that ties premiumization strategy and Hill's pet-nutrition expansion to meaningful upside — rather than a calculated analyst consensus. It is presented here as a point of public discussion, not as a forecast.
Colgate-Palmolive (CL) last traded near $94, after pulling back from a 52-week high around $99. Reaching $115 would require a move of roughly 22%, which should be characterized as substantial for a large-cap consumer staples name. The path would likely depend on a sustained re-rating of the stock's P/E (price-to-earnings ratio) alongside continued earnings growth, since the trailing P/E is already elevated at roughly 37 times GAAP earnings.
The company's fundamentals are mixed but improving. In its second quarter of 2026, net sales rose 4.9% to $5.36 billion, base-business EPS (earnings per share) rose 8% to $0.99, and gross margin expanded 140 basis points to 61.5%. Management raised its 2026 adjusted-EPS outlook to mid-single-digit growth while keeping sales guidance unchanged, a signal of confidence in profitability even as top-line growth remains modest.
The stock's 52-week range runs from roughly $75 to $99, with the recent high near $99 acting as a clear resistance zone. The $100 psychological level sits just above that prior peak, and $115 would require breaking decisively through both. On the downside, support appears in the $90 to $93 area, near levels where the stock consolidated in early 2026. The longer-term structure remains constructive — shares are up meaningfully over the past year — but the $99–$100 band is the first technical hurdle any move toward $115 would need to clear.
Analyst price targets generally reflect a roughly 12-month research horizon, though the $115 public-discussion objective does not carry a specified timeframe. The next major catalyst is the company's third-quarter 2026 earnings report, scheduled for late October 2026, where North America volume trends, gross-margin performance, tariff impacts, and any revision to full-year guidance will be closely watched. Investors should also monitor analyst target revisions, raw-material and fuel costs, and the trajectory of Hill's Pet Nutrition volumes, all of which will shape the credibility of a move toward higher levels.
For traders looking to monitor changing conditions, Tickeron's AI Daily Buy/Sell Signals offer a data-driven complement to fundamental research. The system uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. This can help traders surface new opportunities, track existing positions, and spot trend changes more efficiently than manual review alone. If you are seeking an efficient way to stay ahead of evolving market signals, exploring the AI Daily Buy/Sell Signals platform is a practical next step.
Can Colgate-Palmolive reach $115? The question ultimately hinges on a re-rating toward a premiumization and pet-nutrition growth scenario, because the official analyst targets cluster around $98 and would not support that level on their own. Reaching $115 would require a substantial gain of roughly 22% from current prices, clearing the $99–$100 resistance zone and justifying a valuation that is already elevated. The strongest supports are the raised earnings outlook, margin expansion, and emerging-market and pet-care momentum, while weak North America volumes, tariffs, and a stretched valuation are the principal obstacles. As with any valuation-based objective, $115 represents a possibility rooted in public discussion rather than a guarantee, and the upcoming earnings report will be an important test of the underlying thesis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CL has been closely correlated with PG. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if CL jumps, then PG could also see price increases.